Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 129 publications
DESTINY-Lung06: trastuzumab deruxtecan and pembrolizumab as first-line treatment for HER2-overexpressing, PD-L1 TPS <50% NSCLC.
Journal: Future oncology (London, England)
Published: September 02, 2026
Phase 1/2 study of IMC-C103C, a T cell receptor bispecific (MAGE-A4×CD3) ImmTAC targeting MAGE-A4-expressing malignancies.
Journal: Journal for immunotherapy of cancer
Published: July 07, 2026
First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors.
Journal: Journal for immunotherapy of cancer
Published: May 19, 2026
Real-World Experience of Tarlatamab in Extensive-Stage Small Cell Lung Carcinoma Showed Promising Systemic and Intracranial Efficacy With Higher Neurologic Toxicity.
Journal: JCO precision oncology
Published: April 23, 2026
A phase 1 trial of HPV16 E7 T-cell receptor-engineered T cells in patients with relapsed/refractory HPV16-positive cancers (KITE-439 trial).
Journal: Frontiers in oncology
Published: February 11, 2026
Rewiring the immune response in lung cancer: current progress in bispecific antibodies, CAR-T therapy, and the rise of in vivo CAR-T platforms.
Journal: Frontiers in immunology
Published: December 21, 2025
Long-Term Outcomes After Proton Therapy Versus Intensity Modulated Photon Radiation Therapy With Concurrent Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer: Post Hoc Analysis of a Prospective Randomized Trial.
Journal: International journal of radiation oncology, biology, physics
Published: December 02, 2025
Multi-Institution Analysis of Tarlatamab for the Treatment of EGFR-Mutant Transformed Small Cell Lung Cancer.
Journal: JCO precision oncology
Published: October 30, 2025
A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: April 17, 2025
Phase I study of bevacizumab and temsirolimus combination therapy in advanced malignancies: safety, efficacy, and ovarian cancer expansion.
Journal: The oncologist
Published: April 16, 2025
Phase I Study of Bevacizumab and Temsirolimus Combination Therapy in Advanced Malignancies: Safety, Efficacy, and Ovarian Cancer Expansion.
Journal: The oncologist
Published: April 16, 2025
Last Updated: 09/26/2026